scholarly journals Pharmacological Treatment of Osteoporosis

10.5772/59469 ◽  
2015 ◽  
Author(s):  
Jorge Malouf ◽  
Berta Magallares ◽  
Roberto Güerri
Keyword(s):  
Pharmacological Treatment ◽  
Treatment Of Osteoporosis

Trends in the pharmacological treatment of osteoporosis in Spain from 2000 to 2008

Maturitas ◽  
2013 ◽  
Vol 74 (1) ◽  
pp. 74-78 ◽  
Author(s):  
M. Esther Salgueiro ◽  
Gloria Manso ◽  
Xavier Castells ◽  
Francisco J. Jimeno ◽  
Lucía Ordoñez ◽  
...  
Keyword(s):  
Pharmacological Treatment ◽  
Treatment Of Osteoporosis

Effect of pharmacological treatment of osteoporosis in the prevention of pathological vertebral fractures

Bone ◽  
2014 ◽  
Vol 59 ◽  
pp. 148-149 ◽  
Author(s):  
Paolo Pellegrino ◽  
Carla Carnovale ◽  
Valentina Perrone ◽  
Marco Pozzi ◽  
Dionigi Salvati ◽  
...  
Keyword(s):  
Vertebral Fractures ◽  
Pharmacological Treatment ◽  
Treatment Of Osteoporosis

scholarly journals An overview on the treatment of postmenopausal osteoporosis

2014 ◽  
Vol 58 (2) ◽  
pp. 162-171 ◽  
Author(s):  
Sergio Setsuo Maeda ◽  
Marise Lazaretti-Castro
Keyword(s):  
Quality Of Life ◽  
Vitamin D ◽  
Pharmacological Treatment ◽  
Bone Cells ◽  
Treatment Of Osteoporosis ◽  
Drug Intolerance ◽  
Active Medication ◽  
Novel Drugs ◽  
Substantial Morbidity

Osteoporosis is a worldwide health problem related to the aging of the population, and it is often underdiagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. The lifetime fracture risk at 50 years of age is about 50% in women. The aim of the treatment of osteoporosis is to prevent fractures. Non-pharmacological treatment involves a healthy diet, prevention of falls, and physical exercise programs. Pharmacological treatment includes calcium, vitamin D, and active medication for bone tissue such, as anti-resorptives (i.e., SERMs, hormonal replacement therapy, bisphosphonates, denosumab), bone formers (teriparatide), and mixed agents (strontium ranelate). Bisphosphonates (alendronate, risedronate, ibandronate, and zoledronate) are the most used anti-resorptive agents for the treatment of osteoporosis. Poor compliance, drug intolerance, and adverse effects can limit the benefits of the treatment. Based on the knowledge on bone cells signaling, novel drugs were developed and are being assessed in clinical trials.

scholarly journals Physical approach for prevention and treatment of osteoporosis

2010 ◽  
Vol 54 (2) ◽  
pp. 171-178 ◽  
Author(s):  
Ana Paula Rebucci Lirani-Galvão ◽  
Marise Lazaretti-Castro
Keyword(s):  
Pharmacological Treatment ◽  
Treatment Options ◽  
Mineral Density ◽  
Management Options ◽  
Pharmacological Management ◽  
Treatment Of Osteoporosis ◽  
Specific Strength ◽  
Positive Effects ◽  
Coordination Training

Osteoporosis and its consequent fractures are a major problem in public health. To complement the conventional pharmacological treatment for this metabolic disease, non-pharmacological treatment options have been developed in the last decades. Several studies demonstrate that physical exercise programs including impact exercises, specific strength training, balance and coordination training may maintain or increase spine and hip bone mineral density as well as decrease the frequency of falls among osteoporotic and osteopenic patients. Furthermore, some physical agents such as vibratory platforms, low intensity electrical stimulation, laser therapy and ultrasound show positive effects on osteoporotic tissue as well. Consequently, while planning treatment for an osteoporotic patient, non-pharmacological management options should be considered and integrated to the conventional treatment in order to maximize its effects and improve the quality of life of these patients.

scholarly journals Pharmacological Treatment of Osteoporosis

Osteoporosis ◽  
10.5772/30552 ◽  
2012 ◽  
Author(s):  
Jorge Malouf-Sierra ◽  
Roberto Guerri-Fernandez
Keyword(s):  
Pharmacological Treatment ◽  
Treatment Of Osteoporosis

Pharmacological treatment of osteoporosis for people over 70

2007 ◽  
Vol 19 (3) ◽  
pp. 246-254 ◽  
Author(s):  
Ma Jesús Moro Álvarez ◽  
Manuel Díaz-Curiel
Keyword(s):  
Pharmacological Treatment ◽  
Treatment Of Osteoporosis

scholarly journals Molecular understanding of pharmacological treatment of osteoporosis

2019 ◽  
Vol 4 (4) ◽  
pp. 158-164 ◽  
Author(s):  
Sakae Tanaka
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Pharmacological Treatment ◽  
Bone Remodelling ◽  
Health Concern ◽  
Anabolic Agents ◽  
Treatment Of Osteoporosis ◽  
Turnover Process ◽  
Skeletal Integrity

Osteoporosis is a serious health concern, particularly in aged societies. The burden of osteoporosis with its associated morbidity and mortality due to fracture has become a critical socioeconomic problem. Skeletal integrity is maintained through a balance of bone resorption and bone formation. The bone turnover process, called bone remodelling. Recently, a number of anti-osteoporosis drugs with excellent anti-osteoporosis and fracture effects have been developed. They are mainly classified into two groups according to their effects on bone remodelling: anti-resorptive agents and anabolic agents. Cite this article: EFORT Open Rev 2019;4:158-164. DOI: 10.1302/2058-5241.4.180018

Sign in / Sign up

Export Citation Format

Share Document